inositol has been researched along with Dyslipidemias in 4 studies
Inositol: An isomer of glucose that has traditionally been considered to be a B vitamin although it has an uncertain status as a vitamin and a deficiency syndrome has not been identified in man. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1379) Inositol phospholipids are important in signal transduction.
inositol : Any cyclohexane-1,2,3,4,5,6-hexol.
1D-chiro-inositol : Belonging to the inositol family of compounds, D-chiro-inositol (DCI) is an isomer of glucose. It is an important secondary messenger in insulin signal transduction.
muco-inositol : An inositol that is cyclohexane-1,2,3,4,5,6-hexol having a (1R,2R,3r,4R,5S,6r)-configuration.
Dyslipidemias: Abnormalities in the serum levels of LIPIDS, including overproduction or deficiency. Abnormal serum lipid profiles may include high total CHOLESTEROL, high TRIGLYCERIDES, low HIGH DENSITY LIPOPROTEIN CHOLESTEROL, and elevated LOW DENSITY LIPOPROTEIN CHOLESTEROL.
Excerpt | Relevance | Reference |
---|---|---|
"This new myo-inositol, monacolin K and lipoic acid association contains appropriate substances to contrast various etiopathogenic elements responsible for the onset of PCOS and the symptoms of hyperandrogenism and dyslipidemia related to it." | 5.20 | Polycystic ovary syndrome (PCOS) and hyperandrogenism: the role of a new natural association. ( Cappelli, V; De Leo, V; Di Sabatino, A; Massaro, MG; Morgante, G, 2015) |
"This study was designed to investigate the protective effects of d-Chiro-Inositol (DCI) enriched tartary buckwheat extract (DTBE) against high fructose (HF) diet-induced hyperglycemia and liver injury in mice." | 3.81 | Hypoglycemic and hepatoprotective effects of D-chiro-inositol-enriched tartary buckwheat extract in high fructose-fed mice. ( Guo, J; Hu, Y; Luo, Y; Ren, D; Yang, X; Zhao, Y, 2015) |
"Higher triglyceride and lower HDL levels statistically account for the association between BMI and myo-inositol, pointing toward a potentially critical role for dyslipidemia in the development of cerebral neurochemical alterations in obesity." | 3.79 | Dyslipidemia links obesity to early cerebral neurochemical alterations. ( Gonzales, MM; Haley, AP; Tanaka, H; Tarumi, T, 2013) |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 3 (75.00) | 24.3611 |
2020's | 1 (25.00) | 2.80 |
Authors | Studies |
---|---|
Iervolino, M | 1 |
Lepore, E | 1 |
Forte, G | 1 |
Laganà , AS | 1 |
Buzzaccarini, G | 1 |
Unfer, V | 1 |
Haley, AP | 1 |
Gonzales, MM | 1 |
Tarumi, T | 1 |
Tanaka, H | 1 |
Hu, Y | 1 |
Zhao, Y | 1 |
Ren, D | 1 |
Guo, J | 1 |
Luo, Y | 1 |
Yang, X | 1 |
Morgante, G | 1 |
Cappelli, V | 1 |
Di Sabatino, A | 1 |
Massaro, MG | 1 |
De Leo, V | 1 |
1 review available for inositol and Dyslipidemias
Article | Year |
---|---|
Natural Molecules in the Management of Polycystic Ovary Syndrome (PCOS): An Analytical Review.
Topics: Ascorbic Acid; Dietary Supplements; Dyslipidemias; Fatty Acids, Omega-3; Female; Flavanones; Flavono | 2021 |
1 trial available for inositol and Dyslipidemias
Article | Year |
---|---|
Polycystic ovary syndrome (PCOS) and hyperandrogenism: the role of a new natural association.
Topics: Adult; Antioxidants; Dose-Response Relationship, Drug; Drug Therapy, Combination; Dyslipidemias; Fem | 2015 |
2 other studies available for inositol and Dyslipidemias
Article | Year |
---|---|
Dyslipidemia links obesity to early cerebral neurochemical alterations.
Topics: Adult; Aspartic Acid; Blood Glucose; Blood Pressure; Body Mass Index; Brain; Brain Diseases; Cholest | 2013 |
Hypoglycemic and hepatoprotective effects of D-chiro-inositol-enriched tartary buckwheat extract in high fructose-fed mice.
Topics: Alanine Transaminase; Animals; Aspartate Aminotransferases; Blood Glucose; C-Reactive Protein; Chemi | 2015 |